Many people searching for retatrutide want to know whether it is an approved medication and what stage its research has reached. As of the most recent data, retatrutide does not have an FDA-approved label.
What retatrutide is
Retatrutide, also known by the development code LY3437943, is a compound currently under clinical investigation. No approved product label, brand name, or FDA-sanctioned indication exists for it at this time.
Trial footprint
There are 34 registered clinical trials involving retatrutide. Sampled studies include a completed Phase 1 trial examining retatrutide's effect on metoprolol pharmacokinetics in healthy participants. Two Phase 3 trials are listed as active but not recruiting: one evaluating retatrutide for maintenance of weight reduction in individuals with obesity, and TRIUMPH-Outcomes, which is examining cardiovascular and kidney outcomes in adults living with obesity. These trials reflect ongoing investigation and do not establish approved uses or confirmed benefits.